Panacea Biotec Pharma Appoints Krishan Jalan & Re-appoints Manjula Upadhyay as Directors
Panacea Biotec Pharma Limited approved the appointment of Krishan Kumar Jalan as an additional non-executive independent director from July 1, 2026, until February 13, 2030. Mrs. Manjula Upadhyay was re-appointed as a non-executive independent director for five years from July 23, 2026. Both appointments require shareholder approval.
The appointments of directors to a subsidiary are standard corporate governance procedures and are unlikely to have a significant immediate impact on the overall business operations or financial performance of the parent company.
The announcement pertains to board appointments and re-appointments, which are routine corporate governance activities and do not inherently suggest a positive or negative financial or operational impact on the company.
Panacea Biotec Limited announced significant board-level changes within its material wholly-owned subsidiary, Panacea Biotec Pharma Limited (PBPL).
During a meeting held on May 29, 2026, the Board of Directors of PBPL approved the appointment of Mr. Krishan Kumar Jalan as an additional director in the capacity of a non-executive independent director. His tenure is set to commence from July 01, 2026, and will extend until February 13, 2030, aligning with his current term as an independent director in the parent company, Panacea Biotec Ltd. Mr. Jalan, aged about 68 years, brings over 35 years of experience from the Indian Administrative Service, having held various senior positions including Additional Chief Secretary and Secretary to the Government of India. He is not related to any other director and is not debarred from holding a directorship.
Furthermore, Mrs. Manjula Upadhyay has been re-appointed as a non-executive independent director for a term of five consecutive years, starting from July 23, 2026, to July 22, 2031. Mrs. Upadhyay is a practicing lawyer with approximately 37 years of experience, particularly in labor laws. She holds directorships in other companies and is the Managing Partner of MR Lex Corp LLP. She is not related to any director and is not debarred from holding a directorship. Both appointments are subject to shareholder approval.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under board changes. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.